Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Omadacycline Tosylate

These are related to the Omadacycline Tosylate news, in which you can learn about the updated information in Omadacycline Tosylate, to help you better understand and expand Omadacycline Tosylate market. Because the market for Omadacycline Tosylate is evolving and changing, so we recommend that you collect our website, and we will show you the latest news on a regular basis.
  • Drug Patent & Exclusivity Expiration Report - Week of June 02 2025

    Drug Patent & Exclusivity Expiration Report - Week of June 02 2025

    2025-06-02

    This week, there are 5 drugs in the patent and exclusivity list. They are: - PARATEK PHARMACEUTICALS INC's NUZYRA, containing active ingredient OMADACYCLINE TOSYLATE - SANDOZ INC's CIPRODEX, containing active ingredient CIPROFLOXACIN; DEXAMETHASONE - BRAEBURN INC's BRIXADI, containing active ingredient BUPRENORPHINE - INSMED INC's ARIKAYCE KIT, containing active ingredient AMIKACIN SULFATE - ABBVIE INC's VENCLEXTA, containing active ingredient VENETOCLAX Read More